Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.79 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | BRD2 | P25440 | 3/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30613342 | 1.00 | BRD4 (0.79) | BRD4CREBBPJAK2LMNACYP1A2 | |
| SCHEMBL20004257 | 0.88 | BRD4 (1.00) | BRD4CREBBPJAK2LMNACYP1A2 | |
| SCHEMBL22524503 | 0.80 | BRD4 (0.56) | BRD4CREBBPJAK2LMNACYP1A2 | |
| SCHEMBL15815619 | 0.78 | BRD4 (0.62) | BRD4CREBBP | |
| SCHEMBL17813519 | 0.77 | BRD4 (0.66) | BRD4CREBBPJAK2BRD2 | |
| SCHEMBL6008269 | 0.75 | MAPT (0.50) | BRD4CREBBP | |
| SCHEMBL31143361 | 0.75 | MAPT (0.50) | BRD4CREBBP | |
| SCHEMBL16059774 | 0.75 | BRD4 (1.00) | BRD4CREBBPJAK2LMNABRD2 | |
| SCHEMBL31735610 | 0.75 | BRD4 (1.00) | BRD4CREBBPJAK2LMNABRD2 | |
| SCHEMBL20248269 | 0.74 | BRD4 (0.56) | BRD4CREBBPJAK2BRD2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023194214-A1 | BENZIMIDAZOLE DERIVATIVES FOR PULMONARY ARTERIAL HYPERTENSION | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023194213-A1 | INOBRODIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2023-10-12 | — | — | WO | disclosed |
| EP-4257135-A1 | BENZIMIDAZOLE DERIVATIVES FOR PULMONARY ARTERIAL HYPERTENSION | Justus-Liebig-Universität Gießen (DE) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257130-A1 | INOBRODIB FOR USE IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | Justus-Liebig-Universität Gießen (DE) | 2023-10-11 | — | — | EP | disclosed |
| US-20230027088-A1 | EP300/CBP INHIBITOR | HINOVA PHARMACEUTICALS INC. (CN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027088-A1 | EP300/CBP INHIBITOR | EP300, MLLT1, CREBBP | BRD4 11/4885CREBBP 3/4885JAK2 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.